• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

TG4010：一种针对表达 MUC1 的肿瘤的治疗性疫苗。

TG4010: A therapeutic vaccine against MUC1 expressing tumors.

机构信息

Transgene SA; Illkirch, France.

出版信息

Oncoimmunology. 2012 Aug 1;1(5):791-792. doi: 10.4161/onci.19863.

DOI:10.4161/onci.19863
PMID:22934285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3429597/
Abstract

TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as interleukine 2. Today the clinical development is focused on advanced non-small cell lung cancer in combination with first line chemotherapy. Potential biomarkers predictive of activity have been identified.

摘要

TG4010 是一种基于病毒载体的治疗性癌症疫苗，该病毒载体是一种改良的安卡拉牛痘病毒（MVA），可表达 MUC1 以及白细胞介素 2。目前，该药物的临床开发重点是联合一线化疗治疗晚期非小细胞肺癌。已经确定了一些有预测活性的潜在生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61ed/3429597/5bd214c34f29/onci-1-791-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61ed/3429597/5bd214c34f29/onci-1-791-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61ed/3429597/5bd214c34f29/onci-1-791-g1.jpg

相似文献

1
TG4010: A therapeutic vaccine against MUC1 expressing tumors.TG4010：一种针对表达 MUC1 的肿瘤的治疗性疫苗。
Oncoimmunology. 2012 Aug 1;1(5):791-792. doi: 10.4161/onci.19863.
2
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.基于 MVA 的疫苗和 PD-1/PD-L1 阻断抗体序贯给药可显著改善肿瘤生长和存活：在小鼠肿瘤模型中使用 MVA-βGal 和 MVA-MUC1（TG4010）进行的临床前研究。
Hum Vaccin Immunother. 2018 Jan 2;14(1):140-145. doi: 10.1080/21645515.2017.1373921. Epub 2017 Oct 18.
3
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.一项关于Tg4010（Mva-Muc1-Il2）联合化疗用于III/IV期非小细胞肺癌患者的II期研究。
J Thorac Oncol. 2008 Jul;3(7):735-44. doi: 10.1097/JTO.0b013e31817c6b4f.
4
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.采用表达人MUC1的改良痘苗病毒（MVA）进行I期免疫治疗，作为MUC1阳性晚期癌症患者的抗原特异性免疫治疗。
J Gene Med. 2003 Aug;5(8):690-9. doi: 10.1002/jgm.397.
5
Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.基于痘苗病毒安卡拉株（MVA）的MUC1癌症疫苗与Toll样受体9（TLR9）配体利特莫德（Li28）的序贯给药可增强局部抗肿瘤免疫防御。
Vaccine. 2017 Jan 23;35(4):577-585. doi: 10.1016/j.vaccine.2016.12.020. Epub 2016 Dec 21.
6
Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC.基于病毒的疫苗 TG4010 可诱导特异性免疫应答的拓宽，并改善晚期 NSCLC 的预后。
J Immunother Cancer. 2017 Sep 19;5(1):70. doi: 10.1186/s40425-017-0274-x.
7
Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.放疗与 MVA-MUC1-IL-2 疫苗联合作用可诱导针对 MUC-1 肿瘤抗原的特异性免疫。
J Immunother Cancer. 2017 Jan 17;5:4. doi: 10.1186/s40425-016-0204-3. eCollection 2017.
8
Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors.改良安卡拉牛痘疫苗（MVA）初免-禽痘病毒（FPV）加强疫苗在晚期实体瘤中的Ⅰ期临床试验：表达 brachyury 和共刺激分子的 FPV 疫苗
Oncologist. 2020 Jul;25(7):560-e1006. doi: 10.1634/theoncologist.2019-0932. Epub 2019 Dec 26.
9
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.MVA-MUC1-IL2疫苗免疫疗法（TG4010）可延长前列腺癌生化复发患者的前列腺特异性抗原（PSA）倍增时间。
Invest New Drugs. 2009 Aug;27(4):379-86. doi: 10.1007/s10637-008-9187-3. Epub 2008 Oct 18.
10
Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.DNA 启动的 RNA 复制子和改良安卡拉痘苗病毒 HCV 疫苗接种诱导小鼠产生强效抗丙型肝炎病毒 (HCV) T 细胞免疫应答。
J Virol. 2019 Mar 21;93(7). doi: 10.1128/JVI.00055-19. Print 2019 Apr 1.

引用本文的文献

1
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.非小细胞肺癌中靶向治疗和免疫治疗的耐药机制：克服挑战的有前景策略
Front Immunol. 2024 Apr 9;15:1366260. doi: 10.3389/fimmu.2024.1366260. eCollection 2024.
2
Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy.黏蛋白1作为癌症免疫治疗和靶向治疗的潜在分子。
J Cancer. 2024 Jan 1;15(1):54-67. doi: 10.7150/jca.88261. eCollection 2024.
3
Roles of tissue-resident immune cells in immunotherapy of non-small cell lung cancer.

本文引用的文献

1
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.TG4010 治疗性疫苗联合一线化疗治疗晚期非小细胞肺癌：一项对照 2B 期试验。
Lancet Oncol. 2011 Nov;12(12):1125-33. doi: 10.1016/S1470-2045(11)70259-5. Epub 2011 Oct 21.
2
Summary of presentations from the 11th targeted therapies for lung cancer meeting: immunotherapy and vaccines for treatment of lung cancer.第11届肺癌靶向治疗会议报告总结：肺癌治疗的免疫疗法与疫苗
J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1815-7. doi: 10.1097/01.JTO.0000407570.29900.a5.
3
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
组织驻留免疫细胞在非小细胞肺癌免疫治疗中的作用。
Front Immunol. 2023 Dec 7;14:1332814. doi: 10.3389/fimmu.2023.1332814. eCollection 2023.
4
Lung cancer immunotherapy: progress, pitfalls, and promises.肺癌免疫疗法：进展、陷阱和前景。
Mol Cancer. 2023 Feb 21;22(1):40. doi: 10.1186/s12943-023-01740-y.
5
Post-Translational Modifications in Tumor-Associated Antigens as a Platform for Novel Immuno-Oncology Therapies.肿瘤相关抗原的翻译后修饰作为新型免疫肿瘤治疗的平台
Cancers (Basel). 2022 Dec 26;15(1):138. doi: 10.3390/cancers15010138.
6
Advances in the Lung Cancer Immunotherapy Approaches.肺癌免疫治疗方法的进展
Vaccines (Basel). 2022 Nov 19;10(11):1963. doi: 10.3390/vaccines10111963.
7
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines).晚期 NSCLC 免疫治疗全景：超越 PD-1/PD-L1 抑制剂（CTLA-4、LAG3、IDO、OX40、TIGIT、疫苗）。
Curr Oncol Rep. 2021 Aug 27;23(11):126. doi: 10.1007/s11912-021-01124-9.
8
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?转移性非小细胞肺癌中的免疫检查点抑制剂联合疗法：新选择即将出现？
Immunotargets Ther. 2021 Feb 5;10:9-26. doi: 10.2147/ITT.S253581. eCollection 2021.
9
Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy.作为癌症疫苗的外膜囊泡设计：癌症治疗的新工具包
Cancers (Basel). 2019 Sep 6;11(9):1314. doi: 10.3390/cancers11091314.
10
The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.他达拉非和抗肿瘤疫苗逆转免疫排斥反应也会导致复发性头颈部鳞状细胞癌中 PD-L1 的上调：I 期临床试验的中期分析。
Front Immunol. 2019 May 31;10:1206. doi: 10.3389/fimmu.2019.01206. eCollection 2019.
依匹单抗联合达卡巴嗪治疗未经治疗的转移性黑色素瘤。
N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5.
4
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.一项关于癌症疫苗 TG4010 单药及联合细胞因子治疗转移性肾透明细胞癌患者的 II 期研究：临床和免疫学发现。
Cancer Immunol Immunother. 2011 Feb;60(2):261-71. doi: 10.1007/s00262-010-0935-9. Epub 2010 Nov 11.
5
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.MVA-MUC1-IL2疫苗免疫疗法（TG4010）可延长前列腺癌生化复发患者的前列腺特异性抗原（PSA）倍增时间。
Invest New Drugs. 2009 Aug;27(4):379-86. doi: 10.1007/s10637-008-9187-3. Epub 2008 Oct 18.
6
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.一项关于Tg4010（Mva-Muc1-Il2）联合化疗用于III/IV期非小细胞肺癌患者的II期研究。
J Thorac Oncol. 2008 Jul;3(7):735-44. doi: 10.1097/JTO.0b013e31817c6b4f.
7
Functions of natural killer cells.自然杀伤细胞的功能。
Nat Immunol. 2008 May;9(5):503-10. doi: 10.1038/ni1582.
8
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.采用表达人MUC1的改良痘苗病毒（MVA）进行I期免疫治疗，作为MUC1阳性晚期癌症患者的抗原特异性免疫治疗。
J Gene Med. 2003 Aug;5(8):690-9. doi: 10.1002/jgm.397.